Oncology · Bispecific antibody

Ivonescimab

Ivonescimab is a bispecific antibody that targets PD-1 and VEGF at once. In November 2026 the FDA declined to approve it for EGFR-mutant lung cancer because the HARMONi trial did not show a statistically significant overall survival benefit.

Major setbackFDA issued a Complete Response Letter on November 15, 2026: progression-free survival improved, but overall survival was not statistically significant

Major setback: A pivotal trial missed its main goal, or the FDA declined to approve the drug. Development may continue, and any approvals elsewhere are noted on the profile. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperSummit Therapeutics (partners: Akeso (originator, China))
Drug typeBispecific antibody
TargetPD-1 and VEGF
MechanismBinds both PD-1, releasing a brake on the immune system, and VEGF, a signal tumors use to grow blood vessels, in a single molecule
Other namesSMT112, AK112

Key points

  • Ivonescimab combines two established cancer strategies in one antibody: blocking PD-1 (immunotherapy) and blocking VEGF (anti-angiogenesis).
  • In the China-only HARMONi-2 trial, it beat pembrolizumab on progression-free survival in PD-L1-positive lung cancer: 11.1 versus 5.8 months (hazard ratio 0.51).
  • The global HARMONi trial in EGFR-mutant lung cancer met its progression-free survival endpoint, but overall survival, also a primary endpoint, was not statistically significant (company-reported).
  • On November 15, 2026, the FDA issued a Complete Response Letter, stating that substantial evidence of effectiveness was not established without a statistically significant survival improvement (company-reported).
  • Summit says development continues, including Phase 3 trials in first-line lung cancer (HARMONi-3, HARMONi-7), colorectal cancer, and bladder cancer.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Non-small cell lung cancer
The FDA declined the HARMONi-based application on November 15, 2026 (company-reported). Further lung cancer Phase 3 trials continue. A benchmark is withheld after a pivotal application was turned down.
Complete Response Letter (FDA); Phase 3 ongoing61
56 active · 2 completed · 2 stopped
Not shown (see note)
Other cancers
Includes HARMONi-GI3 (colorectal cancer) and HARMONi-GU1 (bladder cancer), sponsored by Summit, plus many trials in China (registry).
Phase 3120
112 active · 5 completed · 1 stopped
52.4% eventual approval
Phase 3 → application: 57.8%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What ivonescimab is

Ivonescimab is a bispecific antibody: one molecule that binds two different targets.

  • PD-1 is an "off switch" on immune cells that tumors exploit. Blocking it, as pembrolizumab does, frees the immune system to attack cancer.
  • VEGF is a growth factor tumors use to build new blood vessels. Blocking it, as bevacizumab does, can starve tumors and change the environment around them.

Combining both actions in one antibody is intended to deliver more than either alone. Ivonescimab was invented by Akeso, a Chinese biotechnology company. Summit Therapeutics leads its development in the markets covered by the U.S. application.

Clinical evidence

Trials in China

Trial Population Comparison Progression-free survival
HARMONi-A (JAMA, 2024) EGFR-mutant non-small cell lung cancer after TKI therapy (322 patients) Ivonescimab + chemotherapy vs. placebo + chemotherapy 7.1 vs 4.8 months (HR 0.46)
HARMONi-2 (Lancet, 2025) PD-L1-positive non-small cell lung cancer (398 patients) Ivonescimab vs. pembrolizumab 11.1 vs 5.8 months (HR 0.51)

HARMONi-2 drew particular attention as one of the few randomized trials to beat pembrolizumab head to head. Grade 3 or higher treatment-related adverse events occurred in 29% of patients on ivonescimab and 16% on pembrolizumab, while serious immune-related events were similar.

The global HARMONi trial

HARMONi enrolled 420 patients with EGFR-mutant non-squamous lung cancer whose disease had progressed after EGFR-targeted therapy. It compared ivonescimab or placebo, each with chemotherapy. ClinicalTrials.gov lists two primary endpoints: progression-free survival and overall survival.

According to Summit, the trial met its progression-free survival endpoint, but the primary overall survival analysis showed "a positive trend without achieving a statistically significant result." A later post-hoc analysis with longer follow-up reported an overall survival hazard ratio of 0.76 (company-reported).

The FDA's decision

On November 15, 2026, the FDA issued a Complete Response Letter. Summit reported the FDA's position: substantial evidence of effectiveness was not established in the absence of a statistically significant overall survival improvement, and a progression-free survival benefit without one did not support a positive benefit–risk profile.

Scientific perspective

The decision illustrates three principles covered in our guides:

  • Prespecified endpoints decide trials. Overall survival was a primary endpoint, so a "positive trend" did not count as a win. See What Is a Primary Clinical Trial Endpoint?
  • A post-hoc analysis cannot rescue a prespecified one. A later analysis with a favorable hazard ratio is supportive at best. See What Is Statistical Significance in Clinical Trials?
  • Progression-free survival is a surrogate. In settings where survival can be measured, regulators may weigh it heavily, particularly when a drug adds toxicity.

None of this means ivonescimab does not work. The China trials were positive on their primary endpoints. But U.S. approval requires substantial evidence from adequate and well-controlled trials, and here the trial designed to supply it fell short on one of its two co-primary measures.

Development perspective

  • U.S. regulatory status: not approved. openFDA lists no approved application.
  • Next steps: Summit says it will continue development. Registry-listed Phase 3 programs include HARMONi-3 and HARMONi-7 in first-line lung cancer, HARMONi-GI3 in colorectal cancer, and HARMONi-GU1 in bladder cancer.
  • China: Summit reports that Akeso has treated more than 100,000 patients commercially in China (company-reported).
  • Benchmark: withheld. Historical averages for programs at a given phase do not describe a program whose pivotal application was just turned down.

Development timeline

  1. Aug 20, 2024HARMONi-A (China) published: progression-free survival 7.1 versus 4.8 months with chemotherapy in EGFR-mutant lung cancer (HR 0.46). Peer-reviewed
  2. Mar 8, 2025HARMONi-2 (China) published: progression-free survival 11.1 versus 5.8 months against pembrolizumab (HR 0.51). Peer-reviewed
  3. Apr 12, 2025Global HARMONi trial reaches primary completion with 420 patients enrolled. Registry
  4. Jan 2026Summit submits a Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutant lung cancer after TKI therapy. Company-reported
  5. Nov 15, 2026FDA issues a Complete Response Letter: substantial evidence of effectiveness not established without a statistically significant overall survival improvement. Company-reported

What could change the outlook

  • Whether Summit resubmits, and on what evidence, for example longer overall survival follow-up or results from another Phase 3 trial.
  • HARMONi-3 and HARMONi-7, Phase 3 trials in first-line lung cancer, which the registry lists as active or recruiting.
  • Results from the colorectal (HARMONi-GI3) and bladder (HARMONi-GU1) Phase 3 trials.
  • Whether China-generated evidence can support U.S. approval for any indication. The FDA's decision rested on the global trial.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Ivonescimab. Company-reported, not independently verified.

  1. Pipeline updateCompany-reportedNov 18, 2026

    Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Global Registration-Enabling Study to Evaluate...

    Ivonescimab Versus Durvalumab as Consolidation Therapy Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer (NSCLC).

    Company
    Summit Therapeutics Inc.
    Source
    SEC Form 8-K · Other events
  2. RegulatoryCompany-reportedNov 16, 2026

    Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Complete Response Letter Received from FDA for BLA

    Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally...

    Company
    Summit Therapeutics Inc.
    Source
    SEC Form 8-K · Other events
  3. Quarterly reportCompany-reportedNov 4, 2026

    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and...

    The company will continue to provide more details in the coming months with respect to additional Phase III studies evaluating ivonescimab beyond NSCLC, CRC, UC, RCC, BTC, and head and neck squamous cell carcinoma (HNSCC). • In addition to the multiregional studies conducted and sponsored by Summit, Akeso is...

    Company
    Summit Therapeutics Inc.
    Source
    SEC Form 8-K · Financial results

All Ivonescimab disclosures in Pipeline News

Clinical trials

192 registered trials list Ivonescimab as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Non-small cell lung cancer

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT05899608
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Phase 3Active, not recruiting1,600 (est.)Dec 31, 2028 (est.)No
HARMONi-7 · NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Phase 3Recruiting780 (est.)Apr 2028 (est.)No
AK112-311 · NCT07010263
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Phase 3Recruiting560 (est.)Dec 31, 2028 (est.)No
NSCLC · NCT06928389
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Phase 3Recruiting536 (est.)May 2027 (est.)No
NCT05840016
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Phase 3Active, not recruiting532Feb 28, 2025No
NCT06396065
Phase III Study of AK112 for NSCLC Patients
Phase 3Active, not recruiting420Apr 12, 2025No
NCT05499390
AK112 in Advanced Non-Small Cell Lung Cancer
Phase 3Active, not recruiting398Jan 29, 2024No
NCT05184712
Phase 3 Clinical Study of AK112 for NSCLC Patients
Phase 3Active, not recruiting322Mar 10, 2023No
NCT07397338
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2Recruiting370 (est.)May 2029 (est.)No
NCT07669779
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
Phase 2Recruiting348 (est.)Aug 30, 2027 (est.)No
NCT04736823
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
Phase 2Active, not recruiting265Jul 2026 (est.)No
NCT07623356
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Phase 1/2Recruiting265 (est.)Jun 18, 2028 (est.)No
NCT07208773
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Phase 1/2Recruiting260 (est.)Jan 2027 (est.)No
NCT07603791
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
Phase 2Not yet recruiting252 (est.)Dec 30, 2027 (est.)No
NCT05904379
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Phase 1/2Active, not recruiting233 (est.)Jun 30, 2026 (est.)No
NCT07602855
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Phase 1/2Recruiting184 (est.)Jun 22, 2029 (est.)No
NCT07245446
A Study of Ivonescimab in First-Line ES-SCLC
Phase 2Recruiting180 (est.)Dec 2027 (est.)No
NEOINSPIRE · NCT07086326
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
Phase 2Not yet recruiting164 (est.)Dec 30, 2026 (est.)No
NCT07234877
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
Phase 2Not yet recruiting158 (est.)Jan 2032 (est.)No
NCT07742956
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.
Phase 2Not yet recruiting156 (est.)Dec 31, 2027 (est.)No
Apple · NCT06196814
AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC
Phase 1/2Not yet recruiting150 (est.)Mar 1, 2026 (est.)No
NCT07590531
AMT-116 in Combination With AK112 in Patients With Lung Cancer
Phase 1/2Recruiting118 (est.)May 30, 2027 (est.)No
NCT07393555
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
Phase 2Recruiting117 (est.)Nov 30, 2028 (est.)No
NCT04900363
A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC
Phase 1/2Completed108Jun 28, 2024No
NCT05247684
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Phase 2Active, not recruiting90Aug 18, 2025No
NCT06769971
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Phase 2Recruiting80 (est.)Dec 31, 2026 (est.)No
NCT06620796
A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer
Phase 2Not yet recruiting70 (est.)Sep 30, 2026 (est.)No
NCT06951646
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Phase 2Recruiting70 (est.)Jul 1, 2028 (est.)No
NCT07241819
Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2Not yet recruiting66 (est.)Nov 30, 2027 (est.)No
NCT07535437
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Phase 1/2Recruiting66 (est.)Apr 2028 (est.)No
IVO Lung · NCT07204548
The IVO-LUNG Study
Phase 2Not yet recruiting63 (est.)Oct 2027 (est.)No
NCT06478043
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
Phase 2Completed60Jun 30, 2026No
PrE0510 · NCT07057791
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Phase 2Recruiting60 (est.)Dec 2027 (est.)No
AGA TKI NSCLC · NCT07158840
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
Phase 2Not yet recruiting60 (est.)Sep 2028 (est.)No
NCT05636267
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Why stopped (registry): Terminated due to sponsor strategic development reprioritization.
Phase 1/2Terminated59Feb 24, 2025No
NCT06684873
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
Phase 2Not yet recruiting55 (est.)Dec 1, 2027 (est.)No
NCT07535463
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
Phase 1/2Recruiting53 (est.)Apr 2028 (est.)No
ORIGIN2 · NCT07158489
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
Phase 2Recruiting47 (est.)Jul 2028 (est.)No
NCT07405190
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Phase 2Recruiting46 (est.)Mar 1, 2028 (est.)No
NCT06391008
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
Phase 2Unknown status44 (est.)Dec 30, 2024 (est.)No
PEGASUS-Lung · NCT07941583
A Phase II Study of Ivonescimab Combined With Iza-bren in Patients With Advanced Non-Small Cell Lung Cancer.
Phase 2Not yet recruiting43 (est.)Jun 1, 2030 (est.)No
NCT07339839
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
Phase 1/2Not yet recruiting42 (est.)Sep 30, 2027 (est.)No
NCT06820762
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
Phase 2Not yet recruiting40 (est.)Dec 31, 2026 (est.)No
NCT07936578
Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
Phase 2Not yet recruiting40 (est.)Oct 30, 2028 (est.)No
NCT06936644
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
Phase 2Not yet recruiting39 (est.)Apr 30, 2027 (est.)No
NCT07009925
Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.
Phase 2Not yet recruiting38 (est.)May 2027 (est.)No
NCT07594522
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
Phase 1/2Recruiting36 (est.)May 12, 2028 (est.)No
NCT07669051
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
Phase 2Active, not recruiting36 (est.)Jan 1, 2028 (est.)No
NSCLC, YAP · NCT07412262
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
Phase 2Recruiting32 (est.)Mar 31, 2028 (est.)No
GIVEN · NCT07472478
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
Phase 2Recruiting32 (est.)Dec 31, 2027 (est.)No
NCT07489703
SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC
Phase 2Not yet recruiting30 (est.)Dec 31, 2027 (est.)No
NCT07630077
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities
Phase 2Not yet recruiting30 (est.)Jul 1, 2027 (est.)No
NCT06769295
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
Phase 2Recruiting28 (est.)Dec 31, 2026 (est.)No
NCT07038915
STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1
Why stopped (registry): 0 participants
Phase 2Withdrawn0Jul 28, 2025No
7 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06868732
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Phase 1Recruiting288 (est.)Jun 30, 2028 (est.)No
NCT07899086
A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer
Phase 1Not yet recruiting102 (est.)Dec 31, 2027 (est.)No
NCT07619339
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Phase 1Recruiting16 (est.)May 2029 (est.)No
NCT07614646
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients
Phase 1Not yet recruiting13 (est.)Jul 2028 (est.)No
PROMISE · NCT07696832
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
N/ARecruiting265 (est.)May 15, 2027 (est.)No
NCT07359040
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
N/ARecruiting80 (est.)Dec 21, 2026 (est.)No
NCT06766591
Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs
N/ANot yet recruiting36 (est.)Oct 31, 2025 (est.)No

Other cancers

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06930573
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
Phase 4Recruiting30 (est.)May 24, 2026 (est.)No
NCT06953999
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Phase 3Recruiting999 (est.)May 14, 2027 (est.)No
HARMONi-GI3 · NCT07228832
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase 3Recruiting900 (est.)May 31, 2028 (est.)No
HARMONi-GU1 · NCT07815665
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Phase 2/3Recruiting800 (est.)Oct 31, 2030 (est.)No
ILLUMINE · NCT07264075
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
Phase 3Recruiting780 (est.)May 2030 (est.)No
NCT06591520
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Phase 3Active, not recruiting682Oct 2026 (est.)No
NCT06951503
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3Recruiting560 (est.)Jan 13, 2027 (est.)No
NCT06601335
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Phase 3Recruiting510 (est.)Jan 2027 (est.)No
NCT06767527
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Phase 3Recruiting416 (est.)Dec 2026 (est.)No
NCT07765433
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Phase 2/3Not yet recruiting336 (est.)Dec 31, 2028 (est.)No
I-SPY · NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2Recruiting5,000 (est.)Dec 2030 (est.)No
FASCINATE-N · NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2Recruiting716 (est.)Dec 31, 2027 (est.)No
NCT06877650
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Phase 1/2Recruiting436 (est.)Mar 30, 2028 (est.)No
NCT06683846
Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2Recruiting400 (est.)Nov 30, 2027 (est.)No
NCT07560124
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
Phase 1/2Not yet recruiting286 (est.)Jun 6, 2028 (est.)No
NCT06530251
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 1/2Recruiting280 (est.)Jun 2026 (est.)No
NCT05382442
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Phase 2Active, not recruiting254 (est.)May 15, 2026 (est.)No
NCT05951608
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Phase 1/2Active, not recruiting216 (est.)May 1, 2026 (est.)No
NCT07070479
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Phase 2Recruiting208 (est.)Jan 30, 2027 (est.)No
NCT07591090
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Phase 2Recruiting200 (est.)Sep 1, 2027 (est.)No
NCT06560112
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Phase 2Recruiting172 (est.)May 1, 2026 (est.)No
NCT05846867
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Phase 1/2Active, not recruiting170 (est.)May 8, 2026 (est.)No
NCT06790212
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
Phase 2Not yet recruiting168 (est.)Aug 30, 2027 (est.)No
NCT07114315
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Phase 2Recruiting160 (est.)Aug 2027 (est.)No
NCT05214482
A Study of AK112 in Advanced Malignant Tumors
Phase 1/2Completed154Nov 20, 2025No
NCT05229497
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Phase 1/2Active, not recruiting154 (est.)Dec 31, 2026 (est.)No
Huaxi · NCT07374250
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
Phase 2Not yet recruiting154 (est.)Dec 31, 2027 (est.)No
NCT06686030
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
Phase 2Recruiting150 (est.)Oct 2027 (est.)No
NCT07857135
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
Phase 1/2Not yet recruiting140 (est.)Feb 3, 2029 (est.)No
NCT06938321
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Phase 1/2Recruiting135 (est.)May 2027 (est.)No
NCT07636772
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
Phase 2Not yet recruiting132 (est.)Aug 24, 2028 (est.)No
NCT07021950
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Phase 2Not yet recruiting130 (est.)Oct 31, 2027 (est.)No
COLIBRI-GI · NCT07359456
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
Phase 2Not yet recruiting130 (est.)Aug 2029 (est.)No
NCT07394218
ctDNA-guided Treatment Decision-making
Phase 2Recruiting122 (est.)Mar 31, 2028 (est.)No
NCT05227664
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
Phase 2Active, not recruiting120 (est.)Dec 30, 2026 (est.)No
NCT06646055
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Phase 1/2Active, not recruiting110 (est.)Dec 30, 2026 (est.)No
NCT06904300
Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer
Phase 2Not yet recruiting110 (est.)Apr 30, 2028 (est.)No
NeoASPECT · NCT07743632
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC
Phase 2Not yet recruiting110 (est.)Dec 2032 (est.)No
TRIUNITE-03 · NCT06718543
Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
Phase 2Recruiting100 (est.)Oct 31, 2026 (est.)No
NCT07052253
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Phase 2Recruiting100 (est.)May 10, 2027 (est.)No
SMT112-216 · NCT07877194
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
Phase 2Not yet recruiting100 (est.)Apr 12, 2029 (est.)No
NCT06444009
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2Recruiting90 (est.)Dec 1, 2025 (est.)No
NCT06919510
A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer
Phase 2Not yet recruiting90 (est.)Jun 1, 2026 (est.)No
NCT06959550
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
Phase 2Recruiting90 (est.)Jul 1, 2028 (est.)No
NCT07381075
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2Recruiting90 (est.)Dec 31, 2028 (est.)No
GRACIE · NCT06846346
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Phase 2Recruiting88 (est.)Sep 2027 (est.)No
NCT05689853
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Phase 1/2Recruiting87 (est.)Dec 2026 (est.)No
NCT07854600
A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer
Phase 2Recruiting87 (est.)Oct 2028 (est.)No
NCT06814067
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2Not yet recruiting80 (est.)Feb 10, 2029 (est.)No
NCT07885319
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Phase 1/2Recruiting78 (est.)Nov 30, 2028 (est.)No
SEVILLA · NCT06529718
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Phase 2Recruiting72 (est.)Aug 3, 2027 (est.)No
NCT07357220
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
Phase 1/2Not yet recruiting72 (est.)Feb 28, 2027 (est.)No
NCT07091227
Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma
Phase 2Not yet recruiting66 (est.)Jul 20, 2026 (est.)No
NCT07095803
Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure
Phase 2Not yet recruiting60 (est.)Feb 1, 2026 (est.)No
NCT07488572
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
Phase 2Enrolling by invitation60 (est.)Jun 1, 2027 (est.)No
NCT04597541
A Study of AK112 for Advanced Solid Tumors
Phase 1/2Completed59Mar 31, 2022No
NCT06814158
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Phase 2Not yet recruiting57 (est.)Jul 30, 2026 (est.)No
NCT07712094
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
Phase 2Not yet recruiting56 (est.)Feb 27, 2029 (est.)No
NCT07103447
Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC
Phase 2Not yet recruiting54 (est.)Dec 31, 2027 (est.)No
NCT04870177
Study of AK112 in the Treatment of Advanced Gynecological Tumors
Phase 2Completed53May 10, 2024No
NCT06977542
Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer
Phase 2Not yet recruiting53 (est.)Jan 2029 (est.)No
NCT07647016
Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
Phase 2Recruiting53 (est.)Dec 30, 2027 (est.)No
NCT06196697
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
Phase 2Recruiting50 (est.)Jan 2027 (est.)No
NCT06402435
SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer
Phase 2Recruiting50 (est.)Aug 31, 2026 (est.)No
NCT06925724
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Phase 2Recruiting50 (est.)Apr 2027 (est.)No
NCT07244978
Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Phase 2Recruiting49 (est.)Dec 31, 2027 (est.)No
NCT07064902
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Phase 2Not yet recruiting48 (est.)Aug 31, 2026 (est.)No
NCT06791148
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
Phase 2Recruiting45 (est.)Jul 10, 2027 (est.)No
NCT06802666
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Phase 2Recruiting45 (est.)Sep 1, 2026 (est.)No
NCT07385001
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Phase 1/2Recruiting45 (est.)Jan 28, 2027 (est.)No
NCT07809893
Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients
Phase 2Recruiting45 (est.)Dec 31, 2027 (est.)No
ANTHELA · NCT07917481
A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Phase 2Not yet recruiting44 (est.)Jun 2029 (est.)No
NCT07244965
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer
Phase 2Not yet recruiting42 (est.)Jul 1, 2027 (est.)No
AK112 · NCT07565389
Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2Not yet recruiting42 (est.)May 2031 (est.)No
NCT05432492
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Phase 2Completed40Apr 30, 2025No
NCT06760520
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
Phase 2Not yet recruiting40 (est.)Dec 20, 2027 (est.)No
NCT06848842
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
Phase 2Recruiting40 (est.)Jun 2027 (est.)No
NCT06940518
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase 2Recruiting40 (est.)Jan 19, 2028 (est.)No
NCT07070466
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2Recruiting40 (est.)Dec 1, 2026 (est.)No
NCT06145308
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2Recruiting39 (est.)Jul 10, 2028 (est.)No
BALISTA · NCT06793332
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Phase 2Recruiting39 (est.)Dec 31, 2026 (est.)No
Bi-MAPS · NCT06840834
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Phase 2Recruiting38 (est.)Sep 30, 2026 (est.)No
NCT06844422
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
Phase 1/2Recruiting37 (est.)Feb 18, 2028 (est.)No
NCT07188103
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
Phase 2Recruiting37 (est.)Jun 30, 2027 (est.)No
NCT06196775
A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Phase 2Not yet recruiting36 (est.)Jan 31, 2026 (est.)No
NCT06491472
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Phase 2Recruiting36 (est.)Jul 15, 2026 (est.)No
NCT06537011
AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2Not yet recruiting36 (est.)Jul 15, 2027 (est.)No
NCT06593548
Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer
Phase 2Unknown status36 (est.)Nov 1, 2026 (est.)No
I-MAC · NCT06805617
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Phase 2Recruiting35 (est.)Jul 1, 2027 (est.)No
NCT07017673
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Phase 2Recruiting34 (est.)Dec 2027 (est.)No
NCT07226544
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
Phase 2Recruiting31 (est.)Dec 5, 2028 (est.)No
NCT06375486
Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma(uHCC).
Phase 2Unknown status30 (est.)Mar 14, 2025 (est.)No
NCT06472895
A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
Phase 1/2Not yet recruiting30 (est.)Dec 20, 2025 (est.)No
NCT06489197
AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
Phase 2Recruiting30 (est.)Oct 30, 2026 (est.)No
NCT06944106
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Phase 2Recruiting30 (est.)Apr 28, 2026 (est.)No
DIVON · NCT06957561
Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Phase 1/2Not yet recruiting30 (est.)May 1, 2026 (est.)No
NCT06993025
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Phase 2Not yet recruiting30 (est.)Apr 25, 2026 (est.)No
STAR · NCT07162714
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Phase 2Recruiting30 (est.)Mar 31, 2027 (est.)No
NCT07753824
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Phase 2Not yet recruiting30 (est.)Nov 28, 2031 (est.)No
NCT06991491
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
Phase 2Not yet recruiting29 (est.)Jun 30, 2026 (est.)No
NCT07229417
A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
Phase 2Recruiting29 (est.)Sep 30, 2027 (est.)No
SENIOR-HN · NCT07094685
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
Phase 2Recruiting28 (est.)Aug 1, 2027 (est.)No
NCT06980077
Ivonescimab for the Treatment of Thymic Cancer
Phase 2Recruiting25 (est.)Jun 17, 2027 (est.)No
NCT06567314
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Phase 2Recruiting24 (est.)Sep 1, 2028 (est.)No
iTHYM · NCT06750952
Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
Phase 2Not yet recruiting24 (est.)Dec 20, 2026 (est.)No
ICORE-GBC · NCT07767994
AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer
Phase 2Not yet recruiting22 (est.)Jun 30, 2028 (est.)No
NCT07130240
Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer
Phase 2Recruiting20 (est.)Aug 31, 2028 (est.)No
NCT07743138
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Phase 2Not yet recruiting20 (est.)May 1, 2028 (est.)No
NCT04999605
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Why stopped (registry): Too low inclusion rate
Phase 1/2Terminated8Jun 10, 2022No
11 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
ARC-20 · NCT05536141
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Phase 1Recruiting512 (est.)Mar 2029 (est.)No
NCT06929663
A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid Tumors
Phase 1Recruiting166 (est.)Jun 30, 2028 (est.)No
NCT04047290
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Phase 1Completed80Feb 27, 2024No
NCT06913218
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
Phase 1Not yet recruiting60 (est.)Feb 23, 2028 (est.)No
TACE HCC · NCT06990620
TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC
Phase 1Not yet recruiting56 (est.)Jun 2027 (est.)No
NCT07363408
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
Phase 1Not yet recruiting30 (est.)Jul 21, 2027 (est.)No
NCT07650825
OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors
Phase 1Not yet recruiting30 (est.)Jan 31, 2027 (est.)No
NCT07885306
Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Phase 1Active, not recruiting10Aug 13, 2026No
NCT07440212
Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging
N/ANot yet recruiting50 (est.)Dec 30, 2027 (est.)No
NCT06936488
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer
N/AEnrolling by invitation35 (est.)Oct 31, 2026 (est.)No
NCT07686575
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
N/AActive, not recruiting20 (est.)Oct 30, 2026 (est.)No

Clinical pharmacology and supporting studies

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07819591
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
Phase 2Not yet recruiting47 (est.)Dec 1, 2028 (est.)No
NCT06672575
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Phase 1/2Recruiting45 (est.)Jan 31, 2028 (est.)No
NCT07650838
OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS)
Phase 2Not yet recruiting40 (est.)Dec 31, 2027 (est.)No
NCT06809517
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Phase 1/2Recruiting34 (est.)Mar 1, 2026 (est.)No
NCT06637007
Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
Phase 2Unknown status30 (est.)Dec 31, 2024 (est.)No
NCT06875076
Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
Phase 2Recruiting25 (est.)Jan 2028 (est.)No
NCT07516925
A Study of Ivonescimab in People With Leiomyosarcoma
Phase 2Recruiting20 (est.)Apr 2029 (est.)No
NCT07655570
Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma
Phase 2Recruiting10 (est.)May 11, 2027 (est.)No
3 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07340476
A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects
Phase 1Active, not recruiting108 (est.)Apr 10, 2026 (est.)No
NCT06424626
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
Phase 1Enrolling by invitation60 (est.)Dec 31, 2027 (est.)No
NCT05116007
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Phase 1Completed35Dec 4, 2023No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Summit Therapeutics. Form 8-K exhibit: update regarding ivonescimab Biologics License Application (November 15, 2026).Company-reported
  2. Summit Therapeutics. Form 8-K exhibit: BLA submission announcement (January 2026).Company-reported
  3. HARMONi-A Study Investigators; Fang W, et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024;332(7):561–570.Peer-reviewed
  4. Xiong A, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. The Lancet. 2025;405(10481):839–849.Peer-reviewed
  5. ClinicalTrials.gov. HARMONi (NCT06396065).Registry
  6. 21 CFR 314.126: Adequate and well-controlled studies.Statute / regulation
  7. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.